Plant­i­ng an­oth­er flag on Pfiz­er and Al­ny­lam's turf, As­traZeneca grabs amy­loi­do­sis drug from the biotech that in­vent­ed Aduhelm

As­traZeneca — or, more specif­i­cal­ly, its rare dis­ease sub­sidiary Alex­ion — is se­ri­ous about get­ting in­to AT­TR amy­loi­do­sis.

Just weeks af­ter li­cens­ing a late-stage an­ti­sense can­di­date from …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER